Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T8QB
|
|||
| Former ID |
DNC010571
|
|||
| Drug Name |
GLYCYRRHIZIN
|
|||
| Synonyms |
Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Phase 3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C42H62O16
|
|||
| Canonical SMILES |
CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C
|
|||
| InChI |
1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
|
|||
| InChIKey |
LPLVUJXQOOQHMX-QWBHMCJMSA-N
|
|||
| CAS Number |
CAS 1405-86-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
595979, 8145710, 8161234, 12014953, 14767124, 14889369, 29282971, 49974013, 53789412, 57328816, 80458755, 87570348, 93165815, 104069368, 104225159, 104253562, 104335876, 117542241, 118046163, 119525684, 124360077, 124757704, 125164508, 126592383, 134981322, 135985736, 137005264, 137174069, 144205073, 144206976, 144213802, 152032505, 152108764, 160703999, 162037865, 162176852, 163614442, 163883554, 175265976, 178101402, 179316054, 184545284, 196378207, 223673136, 223721543, 223800488, 226407764, 249839445, 252216692, 252391202
|
|||
| ChEBI ID |
CHEBI:15939
|
|||
| SuperDrug ATC ID |
A05BA08
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Resulting Metabolite | 18-beta-glycyrrhetinic acid | |||
| Metabolic Effect | Increase activity | |||
| Description | Glycyrrhizin can be metabolized to 18-beta-glycyrrhetinic acid by Eubacterium, which results in the increase of the drug's activity. | |||
|
Studied Microbe: Eubacterium sp. strain GLH
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Metabolic Reaction | Hydrolysis | |||
| Resulting Metabolite | 18-beta-glycyrrhetinic acid | |||
| Metabolic Effect | Increase activity | |||
| Description | Glycyrrhizin can be metabolized to 18-beta-glycyrrhetinic acid by Eubacterium sp. strain GLH through hydrolysis, which results in the increase of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Alistipes was decreased by Glycyrrhizic acid (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Desulfovibrio
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Desulfovibrio was decreased by Glycyrrhizic acid (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerotruncus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Anaerotruncus was decreased by Glycyrrhizic acid (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Lactobacillus was increased by Glycyrrhizic acid (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Bacteroidetes was increased by Glycyrrhizic acid (p < 0.05). | |||
|
Studied Microbe: Deferribacteres
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Deferribacteres was increased by Glycyrrhizic acid (p < 0.05). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Firmicutes was decreased by Glycyrrhizic acid (p < 0.05). | |||
|
Studied Microbe: Proteobacteria
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Non-alcoholic fatty liver disease | |||
| Description | The abundance of Proteobacteria was increased by Glycyrrhizic acid (p < 0.05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) | Target Info | Inhibitor | [7] |
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolism of xenobiotics by cytochrome P450 | ||||
| Metabolic pathways | ||||
| Chemical carcinogenesis | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Pathwhiz Pathway | Steroidogenesis | |||
| Reactome | Glucocorticoid biosynthesis | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4688). | |||
| REF 2 | ClinicalTrials.gov (NCT01342185) Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B. U.S. National Institutes of Health. | |||
| REF 3 | Gut microbiota: what is its place in pharmacology?. Expert Rev Clin Pharmacol. 2019 Oct;12(10):921-930. | |||
| REF 4 | Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?. Clin Pharmacol Ther. 2019 Aug;106(2):317-328. | |||
| REF 5 | Glycyrrhizin stimulates growth of Eubacterium sp. strain GLH, a human intestinal anaerobe. Appl Environ Microbiol. 1988 Aug;54(8):2027-30. | |||
| REF 6 | Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier. Mol Pharm. 2018 Sep 4;15(9):3860-3870. | |||
| REF 7 | Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.